5 TOP AIM MOVERS OF MONDAY 14 SEPTEMBER 2020
(AIM:SCE ) shares rose 79.59% to 43p with "game-changing" deal
The manufacturer was selected this morning as a tier-one supplier of a carbon ceramic brake disc on a car made by an unnamed automotive original equipment manufacturer
The contract will begin in summer next year and is estimated to be worth £27.5m. The contract currently covers series production to 2024 but may potentially be extended.
"This, truly game changing, award builds upon the recent trend of significant contract wins with mainstream automotive manufacturers,” said Kevin Johnson, CEO of the company.
The Board said it anticipates current FY20 revenues to be around £0.4m higher than market expectations with group revenue for the year expected to increase to around £2.0m.
The Company said it expects to sign further contract awards over the next six months.
According to a research note by Zeus Capital, Surface Transforms is “well positioned to deliver for the medium-term” as a business.
(AIM:SYM ) shares rose 22.22% to 27.5p after positive results
The group reported positive results from a test of its d2p antimicrobial technology masterbatch against a bovine form of COVID-19 which found a virus reduction of 99.84%.
The Institute of Biology at Unicamp University in Brazil tested polyolefin films incorporating the d2p technology for reductions in the presence of the virus at 1, 2 and 24 hour periods.
The tests initially showed a 99.9% reduction in the virus on the polyolefin film at one hour, which then rose to 99.99% at two hours and up to 99.999% at 24 hours.
The Institute concluded in their report that "the products were shown to be virucidal, thus, we recommend the use of such products as potential virucidal agents against coronavirus." It showed the active compound to be active only towards the virus and not the host cells.
“This is another important breakthrough for Symphony, that leads to an exciting commercial phase that will help accelerate our global sales pipeline for d2p already in development,” said Michael Laurier, Chief Executive Officer of Symphony Environmental Technologies.
He added, “These results demonstrate the efficacy against viruses of d2p antimicrobial technology in plastic products, and the importance it has in helping governments to control the spread of the virus and saving lives.”
(AIM:TEK ) shares rose 10% 10.45p after a new technology agreement
Tekcapital said its 100% owned portfolio company, Guident, acquired a new regenerative shock absorber technology designed to extend the driving range of electric vehicles.
The UK investment group said Guident has now acquired the exclusive license to U.S. patent # 8,941,251 from the Research Foundation of the State of New York for an undisclosed sum.
Professor Lei Zuo, the lead inventor of the patent, and Director of the National Science Foundation Center for Energy Harvesting of Materials and Systems said:
"I'm very glad Guident is commercialising this important and highly efficient new technology, which will enable vehicles to be more sustainable by increasing their driving range and improving their ride comfort."
According to Allied Market Research, “the autonomous vehicle market is expected to reach $556 billion by 2026 with a CAGR of 39%,” Tekcapital reiterated this morning to investors.
Alongside a surge in demand for contactless or "touch-free" delivery due to the COVID-19 pandemic, Guident believes this increase will accelerate the roll-out of land-based delivery drones for food and medicines to improve their availability and reduce delivery costs.
TEK believes EV manufacturers are looking for solutions to range anxiety suffered by many EV vehicle owners.
Twitter: Tekcapital Plc
shares increased 13.20% to 3.55p with new CEO
Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020, the drug specialist told investors today.
Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen's appointment.
Dr. Söhngen has established a strong and successful career in the pharmaceutical industry both in the US and Europe and was a co-founder of specialty pharmaceutical firm, Paion AG.
Commenting on the appointment, Proteome’s Sciences Chairman Christopher Pearce said:
“Mariola's time as Chief Medical Officer at Paion together with her international experience and network will bring major benefits to our business as we look to engage more broadly with new and existing clients in the US, Europe and to address the rapidly growing Asian markets."
(AIM:SEE ) shares were up 10.30% at 4.55p with launch of DMS kit
Seeing Machines has announced plans to deliver a fully supported, integrated driver monitoring system (DMS) Kit to the global automotive industry with Qualcomm Technologies.
The technology company intends to launch a fully integrated DMS solution based on its software for the Qualcomm® SnapdragonTM Automotive Development Platform.
The new DMS kit is expected to be available before the end of this calendar year for use by select automotive Tier 1 suppliers as well as original equipment manufacturers.
The DMS Kit supports the company’s full stack DMS solution on the Snapdragon™ ADP targeting integration into either infotainment or centralized ADAS systems, and includes an optimised DMS reference camera, ADP interface board and Seeing Machine’s software.
"Seeing Machines recently launched our embedded product strategy and this collaboration is representative of our e-DME strategic pillar in action,” said Paul McGlone, CEO of SEE.
He added, “We are delighted to be expanding our work with Qualcomm Technologies, a world-leading technology company, to reach more of a fast-moving and maturing market."
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.